Shares of Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) traded up 2.2% during mid-day trading on Monday . The company traded as high as $19.46 and last traded at $18.52, with a volume of 307,212 shares traded. The stock had previously closed at $18.12.

A number of analysts recently issued reports on the stock. Jefferies Group raised their price objective on shares of Bellicum Pharmacueticals from $20.00 to $22.00 and gave the stock a “buy” rating in a report on Tuesday, August 9th. Piper Jaffray Cos. restated a “buy” rating on shares of Bellicum Pharmacueticals in a report on Saturday, July 9th. SunTrust Banks Inc. assumed coverage on shares of Bellicum Pharmacueticals in a report on Thursday, June 2nd. They set a “buy” rating and a $20.00 price objective for the company. Zacks Investment Research upgraded shares of Bellicum Pharmacueticals from a “sell” rating to a “hold” rating in a report on Monday, July 11th. Finally, Citigroup Inc. upgraded shares of Bellicum Pharmacueticals from a “neutral” rating to a “buy” rating and set a $24.00 price objective for the company in a report on Tuesday, August 9th. One investment analyst has rated the stock with a sell rating and five have given a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $27.00.

The firm has a 50-day moving average of $16.17 and a 200-day moving average of $11.98. The firm’s market capitalization is $515.55 million.

Bellicum Pharmacueticals (NASDAQ:BLCM) last announced its earnings results on Monday, August 8th. The biopharmaceutical company reported ($0.61) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.57) by $0.04. During the same quarter in the previous year, the company posted ($0.40) EPS. Analysts expect that Bellicum Pharmacueticals Inc. will post ($2.32) EPS for the current fiscal year.

In related news, insider Kevin M. Slawin sold 67,000 shares of the company’s stock in a transaction dated Monday, August 15th. The shares were sold at an average price of $19.31, for a total value of $1,293,770.00. Following the transaction, the insider now owns 100,079 shares in the company, valued at approximately $1,932,525.49. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, COO Annemarie Moseley sold 25,000 shares of the company’s stock in a transaction dated Thursday, June 2nd. The stock was sold at an average price of $13.00, for a total transaction of $325,000.00. Following the completion of the transaction, the chief operating officer now owns 18,486 shares in the company, valued at approximately $240,318. The disclosure for this sale can be found here.

An institutional investor recently raised its position in Bellicum Pharmacueticals stock. Morgan Stanley boosted its position in Bellicum Pharmacueticals Inc. (NASDAQ:BLCM) by 21.1% during the fourth quarter, according to its most recent filing with the SEC. The firm owned 426,861 shares of the biopharmaceutical company’s stock after buying an additional 74,454 shares during the period. Morgan Stanley owned about 1.61% of Bellicum Pharmacueticals worth $8,653,000 at the end of the most recent quarter.

Bellicum Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on discovering and developing cellular immunotherapies for various forms of cancer, including hematological cancers and solid tumors, as well as orphan inherited blood disorders. The Company uses its chemical induction of dimerization (CID) technology platform to engineer and then control components of the immune system.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.